GSK Biologicals' investigational TB vaccine GSK 692342

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Tuberculosis

Phase 2

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

TerminatedNCT01424501

GlaxoSmithKlineTuberculosis

Start: 2011-11-14End: 2014-04-10Updated: 2018-08-20

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

CompletedNCT01669096

GlaxoSmithKlineTuberculosis

Start: 2012-08-21End: 2013-05-24Updated: 2019-03-22

Related Papers

Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses

PLoS ONE2022-11-105 citations

Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette–Guérin-Vaccinated Adults

Frontiers in Immunology2018-03-2635 citations

Safety and immunogenicity of the M72/AS01 E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study

Tuberculosis2016-07-2275 citations